DDInter1042 DDInter1734
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market.
Tacrine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mechlorethamine
Tacrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dicyclomine
Tacrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxylamine
Tacrine {u} may lead to a major life threatening interaction when taken with {v} Iohexol
Tacrine may cause a minor interaction that can limit clinical effects when taken with Mechlorethamine
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Tacrine may lead to a major life threatening interaction when taken with Iohexol